Article Text
Statistics from Altmetric.com
- DMARDs (biologic)
- Health services research
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
Biological agents revolutionised the treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) as well as Crohn's disease (CD), ulcerative colitis (UC) and psoriasis. RA studies highlighted that uptake of biologic drugs varies strongly across Europe and the income of a country is considered as a major determinant factor for usage.1–3 Putrik et al4 ,5 found that access to biologics in RA—expressed as a composite score of availability, affordability and acceptability—showed a strong positive correlation with gross domestic product (GDP)/capita (r=0.86) in Europe. Much less is known on this topic in AS, PsA and the other three inflammatory diseases.
We analysed real-world biologic usage data and their relationships with GDP/capita in the six inflammatory conditions in Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia. According to our previous literature search, there is no precise and comparable country-specific prevalence data in this region.6–8 Therefore, we estimated the biologic treatment rates per 100 000 inhabitants.
Considering the total of six diagnoses, …
Footnotes
Contributors The study was planned by LG and MP. Data analysis and conducting the study were performed by FR, VB and PB. GyP and ZSz contributed significantly to the interpretation of data and critically revised the content. The manuscript was drafted by LG, FR and MP. All authors reviewed and approved the final version of the manuscript.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data from the study are available.